Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: Effects of estrogen

Christopher L. Hunter, Heather Bimonte-Nelson, Mathew Nelson, Christopher B. Eckman, Ann Charlotte Granholm

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Individuals with Down's syndrome (DS) develop neuropathological features similar to Alzheimer's disease (AD) early in life, including dementia, accumulation of β-amyloid, and irregular phosphorylation of tau proteins. Ts65Dn mice, an animal model of DS, provide a unique method to investigate the mechanisms related to AD-like symptoms in DS and possible therapeutic interventions. Ts65Dn mice undergo a decline in cholinergic phenotype and cognitive deterioration beginning at 6-8 months of age. In middle-aged female Ts65Dn mice, estrogen supplementation alleviated these cholinergic and cognitive impairments. The current study investigated AD-like markers and the effects of estrogen in male Ts65Dn mice. Estrogen treatment prior to behavioral testing did not improve cognitive deficits in 6-month-old male Ts65Dn mice, but decreased total and phosphorylated (pS199) tau in the entorhinal cortex compared to normosomic animals. Hippocampal β-amyloid(1-42) levels were increased in Ts65Dn animals, regardless of estrogen treatment. These findings further support Ts65Dn mice as a model for specific AD-like symptoms, and demonstrate that estrogen treatment of this type does not improve the cognitive ability of male Ts65Dn mice.

Original languageEnglish (US)
Pages (from-to)873-884
Number of pages12
JournalNeurobiology of Aging
Volume25
Issue number7
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Alzheimer Disease
Estrogens
Down Syndrome
Amyloid
Cholinergic Agents
tau Proteins
Entorhinal Cortex
Aptitude
Dementia
Animal Models
Phosphorylation
Phenotype

Keywords

  • β-Amyloid
  • Alzheimer's disease
  • Down's syndrome
  • Estradiol
  • Tau
  • Tau (pS199)
  • Working memory load

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice : Effects of estrogen. / Hunter, Christopher L.; Bimonte-Nelson, Heather; Nelson, Mathew; Eckman, Christopher B.; Granholm, Ann Charlotte.

In: Neurobiology of Aging, Vol. 25, No. 7, 08.2004, p. 873-884.

Research output: Contribution to journalArticle

Hunter, Christopher L. ; Bimonte-Nelson, Heather ; Nelson, Mathew ; Eckman, Christopher B. ; Granholm, Ann Charlotte. / Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice : Effects of estrogen. In: Neurobiology of Aging. 2004 ; Vol. 25, No. 7. pp. 873-884.
@article{c4b6110984e54b60bf197b0d6e618c60,
title = "Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: Effects of estrogen",
abstract = "Individuals with Down's syndrome (DS) develop neuropathological features similar to Alzheimer's disease (AD) early in life, including dementia, accumulation of β-amyloid, and irregular phosphorylation of tau proteins. Ts65Dn mice, an animal model of DS, provide a unique method to investigate the mechanisms related to AD-like symptoms in DS and possible therapeutic interventions. Ts65Dn mice undergo a decline in cholinergic phenotype and cognitive deterioration beginning at 6-8 months of age. In middle-aged female Ts65Dn mice, estrogen supplementation alleviated these cholinergic and cognitive impairments. The current study investigated AD-like markers and the effects of estrogen in male Ts65Dn mice. Estrogen treatment prior to behavioral testing did not improve cognitive deficits in 6-month-old male Ts65Dn mice, but decreased total and phosphorylated (pS199) tau in the entorhinal cortex compared to normosomic animals. Hippocampal β-amyloid(1-42) levels were increased in Ts65Dn animals, regardless of estrogen treatment. These findings further support Ts65Dn mice as a model for specific AD-like symptoms, and demonstrate that estrogen treatment of this type does not improve the cognitive ability of male Ts65Dn mice.",
keywords = "β-Amyloid, Alzheimer's disease, Down's syndrome, Estradiol, Tau, Tau (pS199), Working memory load",
author = "Hunter, {Christopher L.} and Heather Bimonte-Nelson and Mathew Nelson and Eckman, {Christopher B.} and Granholm, {Ann Charlotte}",
year = "2004",
month = "8",
doi = "10.1016/j.neurobiolaging.2003.10.010",
language = "English (US)",
volume = "25",
pages = "873--884",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice

T2 - Effects of estrogen

AU - Hunter, Christopher L.

AU - Bimonte-Nelson, Heather

AU - Nelson, Mathew

AU - Eckman, Christopher B.

AU - Granholm, Ann Charlotte

PY - 2004/8

Y1 - 2004/8

N2 - Individuals with Down's syndrome (DS) develop neuropathological features similar to Alzheimer's disease (AD) early in life, including dementia, accumulation of β-amyloid, and irregular phosphorylation of tau proteins. Ts65Dn mice, an animal model of DS, provide a unique method to investigate the mechanisms related to AD-like symptoms in DS and possible therapeutic interventions. Ts65Dn mice undergo a decline in cholinergic phenotype and cognitive deterioration beginning at 6-8 months of age. In middle-aged female Ts65Dn mice, estrogen supplementation alleviated these cholinergic and cognitive impairments. The current study investigated AD-like markers and the effects of estrogen in male Ts65Dn mice. Estrogen treatment prior to behavioral testing did not improve cognitive deficits in 6-month-old male Ts65Dn mice, but decreased total and phosphorylated (pS199) tau in the entorhinal cortex compared to normosomic animals. Hippocampal β-amyloid(1-42) levels were increased in Ts65Dn animals, regardless of estrogen treatment. These findings further support Ts65Dn mice as a model for specific AD-like symptoms, and demonstrate that estrogen treatment of this type does not improve the cognitive ability of male Ts65Dn mice.

AB - Individuals with Down's syndrome (DS) develop neuropathological features similar to Alzheimer's disease (AD) early in life, including dementia, accumulation of β-amyloid, and irregular phosphorylation of tau proteins. Ts65Dn mice, an animal model of DS, provide a unique method to investigate the mechanisms related to AD-like symptoms in DS and possible therapeutic interventions. Ts65Dn mice undergo a decline in cholinergic phenotype and cognitive deterioration beginning at 6-8 months of age. In middle-aged female Ts65Dn mice, estrogen supplementation alleviated these cholinergic and cognitive impairments. The current study investigated AD-like markers and the effects of estrogen in male Ts65Dn mice. Estrogen treatment prior to behavioral testing did not improve cognitive deficits in 6-month-old male Ts65Dn mice, but decreased total and phosphorylated (pS199) tau in the entorhinal cortex compared to normosomic animals. Hippocampal β-amyloid(1-42) levels were increased in Ts65Dn animals, regardless of estrogen treatment. These findings further support Ts65Dn mice as a model for specific AD-like symptoms, and demonstrate that estrogen treatment of this type does not improve the cognitive ability of male Ts65Dn mice.

KW - β-Amyloid

KW - Alzheimer's disease

KW - Down's syndrome

KW - Estradiol

KW - Tau

KW - Tau (pS199)

KW - Working memory load

UR - http://www.scopus.com/inward/record.url?scp=3042521332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042521332&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2003.10.010

DO - 10.1016/j.neurobiolaging.2003.10.010

M3 - Article

C2 - 15212841

AN - SCOPUS:3042521332

VL - 25

SP - 873

EP - 884

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 7

ER -